© 2015 Fonseca-Santos et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php International Journal of Nanomedicine 2015:10 4981–5003 International Journal of Nanomedicine Dovepress submit your manuscript | www.dovepress.com Dovepress 4981 R e v I e w open access to scientific and medical research Open Access Full Text Article http://dx.doi.org/10.2147/IJN.S87148 Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease Bruno Fonseca-Santos Maria Palmira Daflon Gremião Marlus Chorilli Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNeSP), Araraquara, São Paulo, Brazil Abstract: Alzheimer’s disease is a neurological disorder that results in cognitive and behavioral impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs, often fail due to their poor solubility, lower bioavailability, and ineffective ability to cross the blood–brain barrier. Nanotechnological treatment methods, which involve the design, charac- terization, production, and application of nanoscale drug delivery systems, have been employed to optimize therapeutics. These nanotechnologies include polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and liquid crystals. Each of these are promising tools for the delivery of therapeutic devices to the brain via vari- ous routes of administration, particularly the intranasal route. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Keywords: Alzheimer’s disease, polymeric nanoparticles, solid lipid nanocarriers, microemul- sions, liquid crystals, targeted delivery, nose-to-brain Introduction Alzheimer’s disease (AD) is an acquired disorder of cognitive and behavioral impairment that is an incurable disease with a long and progressive course.1 In AD, plaques develop in the hippocampus,2 a structure deep in the brain that helps to encode memories, and in other areas of the cerebral cortex that are used in thinking and decision making. In the US, an estimated 5.2 million people of all ages have AD. This disease is the sixth leading cause of death in the US overall and the fifth leading cause of death for those aged 65 years and older. Deaths from Alzheimer’s increased by 68% between 2000 and 2010, while deaths from human immunodeficiency virus (HIV), stroke, and heart disease decreased by 42%, 23%, and 16%, respectively. By 2050, the number of people aged 65 years and older with AD may nearly triple from 5 million to a projected 13.8 million unless medical breakthroughs are made to prevent, retard, or stop the disease progression.3 There are several limitations associated with present therapy, and the intranasal strategy seems to be a promising route for delivery of drugs to brain.4 Currently approved drugs for treating the cognitive impairments in AD are based on neurotrans- mitter or enzyme modulation.4 Acetylcholinesterase (AChE) inhibitors are associated with gastrointestinal adverse effects like nausea and vomiting that most commonly lead to discontinuation of treatment.5,6 Tacrine has a short half-life and needs four administrations per day.7 In addition, patients who used the drug required periodic blood monitoring due to hepatotoxicity.8 Also, galantamine and rivastigmine exhibit a half-life of 7 and 2 hours, respectively. The use of memantine can cause adverse Correspondence: Marlus Chorilli Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara-Jaú, km 1, Araraquara, São Paulo, Brazil email chorilli@fcfar.unesp.br Journal name: International Journal of Nanomedicine Article Designation: Review Year: 2015 Volume: 10 Running head verso: Fonseca-Santos et al Running head recto: Nanotechnology-based drug delivery for Alzheimer’s DOI: http://dx.doi.org/10.2147/IJN.S87148 http://www.dovepress.com/permissions.php http://creativecommons.org/licenses/by-nc/3.0/ www.dovepress.com www.dovepress.com www.dovepress.com http://dx.doi.org/10.2147/IJN.S87148 mailto:chorilli@fcfar.unesp.br International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4982 Fonseca-Santos et al effects as dizziness, confusion, constipation, and vomiting.9 A summary of pharmacokinetic parameters of drugs used in AD are shown in Table 1. Therapy failure frequently occurs due to the unfavor- able pharmacokinetics and pharmacodynamics of drugs.12 Pharmacotherapy failure is the result of inadequate physi- cal chemistry of drugs (such as hydrophobicity), unfavor- able absorption by biological membranes, unfavorable pharmacokinetic parameters (such as intense and plasma metabolism), instability of drugs (oxidation, hydrolysis, or photolysis), and toxicity to tissues (hepatotoxicity, neuro- toxicity, or kidney toxicity).12–14 The use of drugs in nano- platforms or nanodevices results in the enhancement of their pharmacokinetics and pharmacodynamics, as well as they can to exhibit minimal toxicity.15,16 On the one hand, an essential aspect in nanomedicine development is the controlled release of drugs into disease sites.12,14,17,18 The effectiveness of a treatment can be increased by incor- porating nanotechnology-based drug delivery systems.19,20 Some of these new platforms, which aim to improve the bioavailability, pharmacokinetics, and pharmacodynam- ics of drugs while reducing their side effects, are shown in Table 2. AD pathophysiology AD is histopathologically characterized by a massive syn- aptic loss and neuronal death observed in the brain regions responsible for cognitive functions, including the cerebral cortex, hippocampus, entorhinal cortex, and ventral striatum.55 In the brain parenchyma of patients with AD, fibrillar amyloid deposits located on the walls of blood vessels are associated with a variety of different types of senile plaques, the accumu- lation of abnormal tau protein filaments, and the subsequent formation of neurofibrillary tangles, neuronal and synaptic loss, glial cell activation, and inflammation.55 Two hypotheses have been proposed for the etiology and pathophysiology of AD: the first hypothesis pertains to amyloidal cascade neuro- degeneration, whereas the second pertains to the dysfunction of the cholinergic system: tau aggregation, metal-mediated toxicity, and inflammation. According to the amyloidal cascade neurodegeneration hypothesis, AD begins with the proteolytic cleavage of the amyloid precursor protein (APP) and results in the production, aggregation, and deposition of β-amyloid (Aβ) and amyloid plaques (Figure 1A).56,57 The deposition of Aβ is increased in patients with AD when there are mutations in APP and presenilin (PS).56,58 An increase in metal-mediated neurotox- icity is also associated with the deposition of Aβ.59 When the concentration of Aβ is high, insoluble amyloid fibers are formed in the brain. These fibers may be complexed with zinc and copper, thereby aggravating the neuronal toxicity.60 Copper has shown the ability to increase Aβ aggregation, and an in vitro study showed that the Aβ–copper complexation resulted in the formation of neurotoxic hydrogen peroxide.61 Furthermore, metals such as copper, iron, and zinc have been found in the amyloid deposits in the brains of AD patients.62 The use of metal chelators in the postmortem tissues of AD patients could dissolve these amyloid plaques.63 An in vivo study with an animal model of AD also showed that chelating agents could solubilize amyloid plaques.64 According to the cholinergic hypothesis, the dysfunction of the cholinergic system is sufficient to produce a memory deficit in animal models that is similar to AD.65 Rossor et al and Henke and Lang reported that the brains of patients with AD showed the degeneration of cholinergic neurons and a reduction in cholinergic markers, whereas the activities of choline acetyltransferase (ChAT) and AChE were reduced in the cerebral cortexes of patients with AD.66,67 A study reported by Soininen et al showed that AD patients carrying the apolipoprotein E (APOE) ε4 allele have a more severe cholinergic deficit than the AD patients without the APOE ε4 allele.68 Phospholipase A2 (PA2) is the enzyme responsible for the synthesis of chemical mediators of inflammation and is also responsible for the conversion of phosphatidylcholine to choline.69,70 However, PA2 has been reported to decrease in the frontal and parietal cortexes of AD patients,71 resulting in decreased levels of choline. Because choline is converted to acetylcholine by ChAT and AChE, its deficit contributes to cholinergic deficiency and AD progression.70 Table 1 Summary of the pharmacokinetic parameters of the cholinesterase inhibitors and memantine Drug Bioavailability (%) tmax (h) Protein binding (%) Half-life (h) Hepatic metabolism Tacrine7 17–37 0.5–3 75 1.3–7.0 CYP1A2, CYP2D6 Donepezil7 100 3–5 96 60–90 CYP2D6, CYP3A4 Rivastigmine7 40 0.8–1.7 40 2 Non-hepatic Galantamine7 85–100 0.5–1.5 18 5–7 CYP2D6, CYP3A4 Memantine10,11 100 3–7 45 60–80 Abbreviations: CYP, cytochrome P450; tmax, time to maximum serum concentration; h, hours. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4983 Nanotechnology-based drug delivery for Alzheimer’s T ab le 2 S um m ar y of n an ot ec hn ol og y- ba se d sy st em s ap pl ie d in t he t re at m en t of A lz he im er ’s d is ea se N an ot ec hn ol og y- ba se d sy st em s D ru g or a ct iv e in gr ed ie nt s M aj or a pp lic at io ns R ou te o f a dm in is tr at io n R ef er en ce s Po ly m er ic n an op ar tic le s T ac ri ne H ig h co nc en tr at io ns o f t ac ri ne a ch ie ve d in t he b ra in R ed uc ed t he t ot al d os e re qu ir ed fo r th e th er ap y In tr av en ou s 21 R iv as tig m in e H ig h co nc en tr at io ns o f r iv as tig m in e ac hi ev ed in t he b ra in In tr av en ou s 22 Pe pt id es T G N a nd Q SH T ar ge te d de liv er y to a m yl oi d pl aq ue s In tr av en ou s 23 Fi br ob la st g ro w th fa ct or In cr ea se d C hA T In cr ea se d bi od is tr ib ut io n w ith in tr an as al a dm in is tr at io n In tr an as al a nd in tr av en ou s 24 U nl oa de d po ly m er ic n an op ar tic le s D is ag gr eg at io n of A β (A β 1- 42 ) In v itr o 25 , 2 6 R iv as tig m in e Im pr ov ed le ar ni ng a nd m em or y ca pa ci tie s In tr av en ou s 27 R iv as tig m in e Im pr ov ed b io av ai la bi lit y en ha nc ed u pt ak e in to t he b ra in In tr an as al 28 Id eb en on e In cr ea se d dr ug s ta bi lit y D ec re as ed d ru g re ac tiv ity In v itr o 29 So lid li pi d na no pa rt ic le s Pi pe ri ne In cr ea se d A C he e nz ym e ac tiv ity R ed uc ed p la qu es a nd t an gl es in t he b ra in In tr ap er ito ne al 30 C ur cu m in a nd d on ep ez il In cr ea se d co nc en tr at io n of d ru gs in t he b ra in Im pr ov ed m em or y an d le ar ni ng in m ic e H ig he r le ve ls o f a ce ty lc ho lin e in b ra in R ed uc ed o xi da tiv e da m ag e In tr an as al 31 v in po ce tin e en ha nc ed b io av ai la bi lit y co m pa re d to t he fr ee d ru g O ra l r ou te 32 R es ve ra tr ol Im pr ov ed c er eb ra l b io av ai la bi lit y Im pr ov ed m em or y O ra l a nd in tr ap er ito ne al 33 Fe ru lic a ci d H ig he r pr ot ec tiv e ac tiv ity o n ne ur on s In v itr o 34 H up er zi ne A Pe rm ea tio n th ro ug h ab do m in al r at s ki n N o pr im ar y ir ri ta tio n ob se rv ed Im pr ov ed c og ni tiv e fu nc tio ns In v itr o Sk in a pp lic at io n 35 C ur cu m in In cr ea se d A C he a ct iv ity In cr ea se d bi od is tr ib ut io n in t he b ra in O ra l r ou te 36 Li po so m es R iv as tig m in e H ig he r co nc en tr at io ns in h ip po ca m pu s, c or te x, a nd o lfa ct or y re gi on en ha nc ed d ru g ph ar m ac od yn am ic s in m ic e In tr an as al 37 R iv as tig m in e Im pr ov ed c og ni tiv e fu nc tio ns a nd m em or y O ra l r ou te 38 Be ta -s he et b lo ck er p ep tid e Pr ev en te d am yl oi d ag gr eg at io n In v itr o 39 C ur cu m in C ro ss ed a B BB m od el In v itr o 40 T ra ns fe rr in M A b an d PA A C ro ss ed a B BB m od el b y tr an sc yt os is p at hw ay In cr ea se d br ai n ta rg et in g In v itr o In tr av en ou s 41 C ur cu m in –P eG d er iv at iv e H ig he r af fin ity b y se ni le p la qu es A bi lit y A β ag gr eg at io n In ta ke n by t he B BB m od el ex v iv o In v itr o 42 C ur cu m in –p ho sp ho lip id c on ju ga te St ro ng ly la be le d A β de po si ts St ai ne d th e A β de po si ts in b ra in o f m ic e ex v iv o H ip po ca m pa l i nj ec tio n 43 Li pi d– cu rc um in d er iv at iv es H ig he r af fin ity fo r A β 1- 42 fi br ils In v itr o 44 G al an ta m in e an d a lig an d- fu nc tio na liz ed pe pt id ea U pt ak e in to P C 12 n eu ro na l c el ls In v itr o 45 (C on tin ue d) www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4984 Fonseca-Santos et al The main function of tau protein is to promote the asso- ciation of tubulin monomers in order to form microtubules, which modulate the functional and structural organization of neurons.72 In AD, tau protein is abnormally phosphorylated and thus the microtubules disaggregate, accumulating in the cell body and forming intracellular filaments that lead to the disorganization of the neuron cytoskeleton.73,74 This results in the blocking of the intracellular trafficking of neurotrophic proteins and other functional proteins, result- ing in the loss or decline in dendritic or axonal transport in neurons (Figure 1B). In AD, the reactive astrocytes are increased,75,76 and there is a high expression of PA2. Astrocytes are able to release proinflammatory molecules, such as interleukins (ILs), prostaglandins, leukotrienes, thromboxanes, coagulation factors, complement factors, and proteases.77–80 The activated microglia cells have also been shown to be abundant in the brains of patients with AD.76,79 These cells produce a variety of neurotoxic compounds, including superoxide radicals, glu- tamate, and nitric oxide.81 The exposure of microglia cells to Aβ results in the release of proinflammatory factors, includ- ing interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α).82 A number of complex mechanisms are involved in the genesis and progression of AD. Recent advances in the understanding of the molecular control of these various pathways will allow for a more accurate diagnosis and assessment of AD prognosis and may lead to more novel approaches to finding new molecular targets for AD treat- ment and prevention. Diagnosis and treatment of AD AD is a clinical diagnosis;83–86 however, the differential diag- nosis of AD is based on the diagnosis of depression, which occurs in approximately 30%–50% of patients with AD. Depression in patients committed with AD are more often features motivational disturbances, such as fatigue, psycho- motor slowing, and apathy, whereas depression in geriatric patients without cognitive impairment tends to feature mood symptoms, such as depressed mood, anxiety, suicidality, and disturbances in sleep and appetite.87 Commonly used instru- ments for assessing depression were designed for use in other patient populations and may be less reliable in patients with AD.87 Olin et al have proposed the inclusion and exclusion of provisional affective and behavioral diagnostic criteria in identifying AD in patients with depression.88 Ancillary imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI) and, in selected R iv as tig m in e H ig he st A C he in hi bi tio n en ha nc ed b io av ai la bi lit y In tr an as al In tr av en ou s 46 R iv as tig m in e H ig he st A C he in hi bi tio n O ra l r ou te a nd in tr ap er ito ne al 47 R iv as tig m in e D ru g pe rm ea te d th ro ug h cu ltu re d C ac o- 2 ce lls A C he in hi bi te d in t he b ra in In v itr o O ra l r ou te 48 Fo lic a ci d A bs or be d th ro ug h th e na sa l c av ity In tr an as al 49 G in kg o bi lo ba e xt ra ct A cc um ul at ed in t he b ra in In cr ea se d th e ac tiv iti es o f a nt io xi da nt e nz ym es O ra l r ou te 50 G . b ilo ba e xt ra ct H ig h co nc en tr at io n of fl av on oi d gl yc os id e bi om ar ke r in t he b ra in O ra l 51 N an oe m ul si on s C ur cu m in Im pr ov ed m em or y an d le ar ni ng In tr an as al 31 H up er zi ne A Im pr ov ed c og ni tiv e fu nc tio n T ra ns de rm al 35 β- A sa ro ne Im pr ov ed b io av ai la bi lit y In tr an as al 52 Ta be rn ae m on ta na d iva ric at e St ab le fo rm ul at io ns In cr ea se d sk in p er m ea tio n an d re te nt io n T ra ns de rm al 53 M ic ro em ul si on s T ac ri ne R ap id ly a bs or be d th ro ug h no se t o br ai n Im pr ov ed m em or y In tr an as al 54 Li qu id c ry st al s T. d iva ric at e St ab ili ty o f d ru g in fo rm ul at io ns In cr ea se d sk in p er m ea tio n an d re te nt io n T ra ns de rm al r ou te 53 N ot e: a P ep tid e no t sp ec ifi ed in t he r ef er en ce . A bb re vi at io ns : A C he , a ce ty lc ho lin es te ra se ; B BB , b lo od –b ra in b ar ri er ; C hA T , c ho lin e ac et yl tr an sf er as e; M A b, m on oc lo na l a nt ib od y; P A A , p ep tid e an al og o f a po lip op ro te in ; P eG , p ol ye th yl en e gl yc ol . T ab le 2 (C on tin ue d) N an ot ec hn ol og y- ba se d sy st em s D ru g or a ct iv e in gr ed ie nt s M aj or a pp lic at io ns R ou te o f a dm in is tr at io n R ef er en ce s www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4985 Nanotechnology-based drug delivery for Alzheimer’s cases, single-photon emission CT (SPECT) or positron emission tomography (PET), can also be used in the diagnosis of AD.89 Brain MRI or CT scanning has indicated the use of structural neuroimaging to detect lesions that may result in cognitive impairment. In patients with AD, brain MRIs or CT scans can show diffuse cortical and cerebral atrophy, but these findings are not diagnostic of AD.89 Images obtained from CT scans can show the changes in the rate of atrophy progression,90 longitudinal changes in brain size,91 and enlargement of the third and lateral ventricles.92 This approach can be useful in diagnosing AD. MRI measurements of the cerebral structures (hippocam- pus, amygdala, lateral ventricles, third ventricle, and basal forebrain) yield a prediction rate of 77% for the conversion of questionable AD to AD.93,94 PET scanning is helpful for understanding the pathogenesis of AD, making the correct diagnosis, and monitoring the AD progression and response to drug treatment.95 PET scanning involves the introduction of a radioactive tracer into the human body, usually via intravenous injection. PET measures glucose-dependent physiological processes in brain by using 2-[18F]fluoro- 2-deoxy-d-glucose (FDG).96,97 Patients with AD have a temporoparietal glucose hypometabolism, which correlates with the severity of dementia and can be evaluated using FDG PET.96,98,99 In 2012, florbetapir F18 was approved by the US Food and Drug Administration (FDA) as a diagnostic imaging agent. It is indicated for PET brain imaging of Aβ neuritic plaques in adults under evaluation for AD or other conditions related to cognitive decline.100–103 In 2013, the FDA approved flutemetamol F18. Like florbetapir F18, this drug attaches to Aβ in the brain and produces a PET image that can be used to assess the presence of Aβ, as evidenced in a clinical Phase II trial.104 Laboratory tests can be used to exclude other possible causes for dementia89 such as cerebrovascular disease, cobala- min deficiency, syphilis, or thyroid disease.105–107 Cerebrospi- nal fluid (CSF) analysis can be useful in identifying dementia caused by other factors, including infections in the central nervous system (CNS) such as neurosyphilis, neuroborrelio- sis, and cryptococcosis.108 The CSF levels of tau and phospho- rylated tau are often elevated in AD, whereas amyloid levels are usually low. The reason for this is not known, but perhaps amyloid levels are low because the amyloid is deposited in the brain rather than the CSF.86 Other diagnosis tools include genotyping mutations in the genes for APOE, APP, and PS. A recent study has reported that plasma levels of APOE ε4 are associated with the risk of dementia independent of the APOE genotype.109 These genotype tests provide assessments to patients with AD and provide the key elements used in genetic counseling for the disease.110 The use of nanotechnology as a diagnostic tool depends on the detection of amyloid peptides (Aβ), which are used as targets in the development of biological markers for the diagnosis of AD. β Figure 1 Formation of amyloid plaques (A) and neurofibrillary tangles (B) in the neurons in Alzheimer’s disease. Abbreviations: Aβ, β-amyloid; APP, amyloid precursor protein. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4986 Fonseca-Santos et al Polymeric nanoparticles (NPs) have been prepared and encapsulated with radio-labeled 125I-clioquinol (5-chloro-7- iodo-8-hydroxyquinoline [CQ]), a drug with amyloid affin- ity, to improve its transport to the brain and amyloid plaque retention of 125I-CQ. Radio-iodinated CQ NPs have been demonstrated to be promising delivery vehicles for in vivo SPECT or for use as a PET amyloid imaging agent.111 The use of thioflavin-T entrapped in polymeric NPs has been described for use as a probe to detect Aβ in senile plaques.112 The photoconversion of fluorescent thioflavin-T as a model drug was achieved in tissues fixed 3 days after injection, and thioflavin-T delivered from nanospheres was predominantly found in neurons and microglia. These data suggest that drugs delivered by NPs might target Aβ in the brain.112 The current pharmacological approach to AD treatment is based on vascular prevention and symptomatic therapy with cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) antagonists.113 Cholinesterase inhibitors are included in drugs such as donepezil, rivastigmine, galantamine,113 and tacrine.114 These drugs act by inhibiting the action of AChE and optimizing the levels of acetylcholine available for postsynaptic stimulation.115 Memantine is an NMDA antagonist that acts as a non- competitive glutamate receptor antagonist.116,117 Glutamate- related excitotoxicity resulting from an excessive activation of neuronal amino acid receptors118 is involved in the pathophysiology of AD.119 Memantine acts on the glutamater- gic system by blocking NMDA receptors and this blocking effects on glutamate activity reduction on brain cells and blocking the activity of the neurotransmitter.120,121 At normal levels, glutamate is conducive to memory and learning, but if levels are too high, glutamate appears to overstimulate nerve cells, killing them through excitotoxicity.122 The interaction of memantine with NMDA receptors plays a major role in the symptomatic improvement that the drug produces in AD. Moreover, there is no evidence as yet that the ability of memantine to protect against NMDA receptor-mediated excitotoxicity has a disease-modifying effect in AD, although this has been suggested in animal models.123 Winslow et al have reported conflicting evidence about the benefits of selegiline, testosterone, and ginkgo (Ginkgo biloba) for the treatment of AD, and no evidence supports the beneficial effects of vitamin E, estrogen, or nonsteroi- dal anti-inflammatory drug therapies.114 Nevertheless, the inflammatory pathways in AD124,125 and treatment with anti- inflammatory molecules has the potential to delay, prevent, or treat AD.125,126 Nanotechnology-based drug delivery systems Treatment options are limited mainly due to the inability of drugs to cross the blood–brain barrier (BBB)127–129 or their poor solubilities by oral route.130,131 Many strategies have been developed to overcome the BBB, such as drug delivery systems, liposomes, polymeric and solid lipid NPs (SLNs), solid lipid carriers, liquid crystals (LCs), microemulsions (MEs), and hydrogels.127–129,132–134 The physicochemical characteristics of drugs, such as its hydrophilicity or lipo- philicity, ionization, high molecular weight, poor bioavail- ability, extensive metabolization, and adverse effects, can result in its failure as a pharmacotherapeutic.127,135 These limitations can be overcome by the use of intranasal admin- istration, which offers an alternative, noninvasive means of drug delivery to the brain because drugs delivered this way can bypass the BBB and directly transport drugs to the CNS.136,137 Polymeric NPs NPs are defined as particulate dispersions or solid particles with sizes ranging from 1 to 1,000 nm.138 The structural organization of a nanosystem is based on its composi- tion: the presence of compartments within nanocapsules139 leads to oily or aqueous cores surrounded by thin polymer membranes,140 whereas nanospheres provide a matrix-based organization of the polymeric chains (Figure 2).139 NPs have been prepared using several methods, including polymer polymerization,141,142 ionic gelation or coacervation,143,144 emulsion solvent evaporation,145–148 spontaneous emulsifica- tion or solvent diffusion,149,150 nanoprecipitation,151,152 spray drying,29,153 supercritical fluid technology,154 and particle rep- lication in non-wetting templates (PRINT).155–157 Drug delivery across the BBB to the brain may provide a significant advantage over currently used strategies without damaging the BBB.158,159 The transport mechanism of NPs across the BBB can be explained by the increased retention of the NPs in the brain blood capillaries in combination with the adsorption of the NPs to the capillary walls. These events lead to a higher concentration gradient, which increases the transport across the endothelial cell layer and thus enhances the delivery to the brain.160 Transport can also be facilitated through the inhibition of the efflux system160 by using polysorbate 80 as the coating agent.161,162 NPs may induce local toxic effects on the brain vasculature, leading to a lim- ited permeabilization of the brain endothelial cells.160 The use of a surfactant to solubilize the lipids of the endothelial cell membrane can enhance drug permeability across the www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4987 Nanotechnology-based drug delivery for Alzheimer’s BBB. The NPs could permeate the BBB through the tight junctions, which are open between the endothelial cells of the brain blood vessels.158,160,163 Endocytosis by the endothelial cells followed by the release of the drugs within these cells facilitates delivery to the brain.164,165 Transcytosis can also facilitate transport through the endothelial cell layer.166–168 Finally, a combination of the effects described above can be used (Figure 3).158,160,163 NPs can also be administered nasally to promote absorption169 and delivery to the brain.160,170,171 Other technological strategies include coating NPs with polyethylene glycol (PEG),172 polymers, or antibodies to improve nasal absorption.173 Surface modification of the NPs with mucoadhesive polymers can increase the retention time of NPs delivered via the nasal route.174 Wilson et al21 developed polysorbate 80-coated poly(n- butyl cyanoacrylate) NPs loaded with tacrine, which were prepared by emulsion polymerization. The concentrations of tacrine in the lungs and kidneys were not significant when compared to both groups. The authors suggested a mechanism for delivery of the coated polysorbate 80 NPs to the brain via the interaction between the polysorbate 80 coating and the endothelial cells of the brain microvessels.21 In another study, Wilson et al22 developed poly(n-butyl cyanoacrylate) NPs coated with polysorbate 80 for the targeted delivery of rivastigmine to the brain in order to treat AD. Animal studies were performed by injecting the NPs into mice. The concentration of tacrine in the brain was approximately 170 ng/mL when the coated NPs were used, and this result was significant (P,0.001) relative to the use of uncoated NPs or the free drug. The authors suggest that the mechanism for delivering the coated polysorbate 80 NPs to the brain is the interaction between the polysorbate 80 coating and the endothelial cells of the brain microvessels.22 This specific role of the polysorbate 80 coating in targeting NPs to the brain was proposed and studied by Sun et al.175 Zhang et al23 developed a dual-functional NP drug deliv- ery system based on a PEGylated poly(lactic acid) polymer containing two targeting peptides, TGN and QSH, conjugated to the surfaces of the NPs. TGN specifically targets ligands at the BBB, while QSH has good affinity for Aβ 1-42 , which is the main component of amyloid plaques. In this study, the optimal maleimide/peptide molar ratio was 3 for both TGN and QSH on the surface of the NPs. These NPs were delivered to amyloid plaques with enhanced and precisely targeted delivery in the brains of AD model mice.23 Polymeric matrix Polymeric shell Lipid matrix Nanoparticle Drug Lipid shell Oil coreOil core Polymeric nanocapsule Solid lipid nanoparticle Lipid nanocarrier Polymeric nanosphere Figure 2 Schematic differences between nanocapsule, nanostructured lipid carrier, polymeric nanoparticle, and solid lipid nanoparticle drug delivery systems. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4988 Fonseca-Santos et al The use of intranasal NPs to deliver basic fibroblast growth factor (bFGF) to the brain for the treatment of AD was also studied by Zhang et al.24 In this study, bFGF was entrapped in NPs conjugated with PEG and polylactide-polyglycolide (PLGA) and Solanum tuberosum lectin (STL), which selec- tively binds to N-acetylglucosamine on the nasal epithelial membrane to facilitate brain delivery. The NPs were prepared using the emulsion solvent evaporation method. The intrana- sal administration of the STL-modified NPs (STL-bFGF-NPs) resulted in a 1.7–5.17-fold greater distribution of the formula- tion in the brain than the intravenous administration of the NPs. The distribution of the formulation using intranasally admin- istered STL-bFGF-NPs was also 0.61–2.21-fold greater than an intranasally administered drug solution and 0.19–1.07-fold greater than intranasally administered unmodified NPs. The activity of ChAT in mice showed a significant increase (P,0.05) in the group treated with NPs via the intranasal route compared to the AD control group. These findings indicated that ChAT activity in the hippocampus of AD rats treated with bFGF-loaded STL-conjugated NPs was higher than in the rats treated with unconjugated NPs. The STL-conjugated NPs could effectively facilitate the direct transport of bFGF into the rat brain with reduced peripheral adverse effects following intranasal administration.24 Based on these requirements, PEG–PLGA copolymer NPs that fea- ture a PEG-rich surface around the PLGA core are ideal for intranasal administration because the PEG-rich surface has been demonstrated to prevent the NP aggregation typically observed when the uncoated PLGA NPs come into contact with the nasal mucosa.176 Poly[(hexadecyl cyanoacrylate)-co-methoxypoly (ethylene glycol) cyanoacrylate] NPs were formulated by Brambilla et al.25,26 The authors investigated the effects of these NPs in slowing down or disrupting the aggregation process in vitro through kinetic studies performed with the Aβ 1-42 peptide or corresponding oligomers by capillary electrophoresis. The capillary electrophoresis experiments showed that these NPs could link the Aβ 1-42 peptide both under its monomeric and soluble oligomeric forms. These NPs were also shown to influence Aβ 1-42 peptide aggregation, which was confirmed by thioflavin-T assays. Joshi et al27 used a modified nanoprecipitation method and an emulsion polymerization method to prepare rivastigmine- loaded PLGA and PBCA NPs, respectively. The administra- tion of rivastigmine formulations in saline-treated animals did not result in any noticeable improvement in learning and memory capacities, whereas the administration of dif- ferent rivastigmine-loaded NPs in scopolamine-treated mice antagonized the scopolamine-induced amnesia, as evidenced by a significant decrease (P,0.05) in escape latency. Fazil et al28 prepared chitosan NPs using an ionic gelation method to enhance the bioavailability and uptake of rivastig- mine to the brain via intranasal delivery. Using confocal laser scanning fluorescence microscopy, their findings showed Figure 3 Schematic representation of types of liposomes and enlarged view of the layers of phospholipids. Abbreviations: GUv, giant unilamellar vesicle; LUv, large unilamellar vesicle; MLv, multilamellar vesicle; SUv, small unilamellar vesicle. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4989 Nanotechnology-based drug delivery for Alzheimer’s that the concentration of rivastigmine in the brain following intranasal administration was found to be significantly higher at all times compared to the administration of a rivastigmine solution via the intravenous or intranasal route.28 Amorim et al used the spray-drying technique to develop idebenone-loaded chitosan and N-carboxymethylchitosan NPs.29 Although the authors did not study the use of these NPs in the treatment of AD, the beneficial effects of idebenone for the treatment of AD177,178 and its role as an antioxidant in AD progression55,58,179–181 have been well documented in clinical trials. The incorporation of idebenone in chitosan or N-carboxymethylchitosan NPs was shown to preserve the antioxidant efficiency, especially at higher polymer-to-drug ratios. The NPs showed a tenfold increase in drug stability compared to the free drug. These results showed a severe reactivity of free idebenone that was similar to the positive control, indicating a significant potential for corrosion or irritation. On the other hand, the incorporation of idebenone in polymeric NPs showed a decrease in drug reactivity.29 Because chitosan and N-carboxymethylchitosan exhibit mucoadhesive properties,182–187 these results revealed that NPs are potential carriers for the nasal delivery of hydrophobic and irritating drugs such as idebenone due to the high first- pass metabolism of idebenone188 after oral administration. Solid lipid carriers SLNs are typically spherical, with average diameters between 10 and 1,000 nm when dispersed in water. SLNs possess a solid lipid core matrix that can solubilize lipophilic molecules.189 The lipid core, typically consisting of triglyc- erides (eg, tristearin), diglycerides (eg, glyceryl behenate), monoglycerides (eg, glycerol monostearate), fatty acids (eg, stearic acid), steroids (eg, cholesterol), or waxes (eg, cetyl palmitate),190 is stabilized by surfactants, though the combi- nation of emulsifiers might be more efficient at preventing particle agglomeration.190 Though SLNs are formed by a matrix lipid, a new generation of NPs can be produced using a blend of solid lipids with a liquid lipid, termed nanostruc- tured lipid carriers (NLCs),189,191 in order to minimize the drug expulsion associated to SLNs (Figure 2). SLNs or NLCs are prepared from lipids, an emulsifier, and water or solvent by using different methods such as high pressure homogenization,192,193 an ultrasonication/high-shear technique,194–198 the solvent evaporation method,199,200 the solvent emulsification-diffusion method,201–204 the super- critical fluid method,205,206 the ME-based method,207–209 the spray-drying method,210–212 the double emulsion method,213 or the precipitation technique.214 The BBB can be overcome through the use of SLNs or nanocarriers lipids for the delivery of drugs to the brain, as these formulations can penetrate the BBB194 or be used intranasally to bypass the BBB. The use of cationic lipids can be a strategy to improve mucoadhesion in the nasal cav- ity by promoting electrostatic interactions with mucus215 in addition to mediating the adsorptive-mediated transcytosis cationic NPs across the BBB.216 Coating NPs with surfactants can be an alternative strategy for delivery across the BBB. The transport of surfactant-coated NPs across the BBB may occur through endocytosis mediated by the endothelial cells of the brain capillaries.217–219 Piperine SLNs with a polysorbate 80 coating were pre- pared by the emulsification-solvent diffusion technique.30 These NPs were experimentally assessed in ibotenic acid- induced AD in mice. The results showed an increase in AChE activity and improvement in cognition, which were superior to the result shown for donepezil. Histopathology studies also revealed a reduction in plaques and tangles.30 Sood et al31 developed curcumin/donepezil-loaded NCLs for delivery to the brain via the intranasal route. The results demonstrated a higher concentration of drugs in the brain via intranasal delivery compared to intravenous administration. A mouse model showed improved memory and learning compared to the group treated with the free drug. Neverthe- less, the levels of acetylcholine were improved and oxidation damage was reduced in the groups treated with NLCs.31 Zhuang et al32 formulated vinpocetine-loaded NCLs using a high-pressure homogenization method for improved oral bioavailability. Pharmacokinetic studies showed a twofold increase, threefold increase, and 0.35-fold decrease in the maximum concentration, maximum time, and elimination constant in plasma, respectively, relative to a suspension of vinpocetine. The authors concluded that the NCLs showed a relative drug bioavailability of 322% in rats after oral administration compared with the administration of free drug in suspension, further demonstrating that these NCLs can be used to load drugs with poor water solubility. AD- based clinical trial has shown that vinpocetine is a drug with potential use in the treatment of cognitive impairment and memory.220 However, a 2003 Cochrane Review determined that the results were inconclusive.221 NCLs with oil-based cores loaded with resveratrol were developed by Frozza et al in order to improve cerebral bioavailability.33 The results showed 2.5-fold, 6.6-fold, and 3.4-fold greater drug concentrations in the brain, liver, and kidneys, respectively, of mice treated with the NCLs relative to those treated with free resveratrol.33 Additional www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4990 Fonseca-Santos et al important data showed that mice treated with an intrac- erebral infusion of Aβ 1-42 had memory deficits that were reduced only by the treatment with drug-loaded NCLs with oil-based cores.33 Recently, a study using resveratrol confirmed the accumulation of this drug in vivo and the neuroprotective action of a kinase against Aβ plaques.222 This study demonstrates the emerging therapeutic potential of resveratrol in AD. Bondi et al223 developed ferulic acid-loaded SLNs using the ME technique as a potential treatment for AD. In this study, unloaded SLNs showed no cytotoxicity against human neuroblastoma, but they showed the ability to pen- etrate into these cells. Cells treated with ferulic acid-loaded SLNs showed a greater reduction in the production of radi- cal oxygen species than cells treated with the free drug.223 These findings demonstrate that drug-loaded SLNs possess a higher protective activity than the free drug against oxida- tive stress induced in neurons, suggesting that these SLNs are potentially excellent carriers for transporting cholinergic agent drugs into the cells. Patel et al proposed a study to comparatively evaluate the in vitro and in vivo behaviors of huperzine A-loaded lipid-based nanocarriers.35 Huperzine A is a well-tolerated drug that has been shown in a clinical study to effectively reverse or attenuate cognitive deficits.224 Huperzine A was loaded on SLNs and NLCs, which were prepared using the ME technique before the nanocarriers were dispersed on a gel. Ex vivo permeation studies were carried out, and the results showed that NLCs had increased permeability through the abdominal rat skin relative to SLNs. A primary irritation test in rabbit model indicated the safety of applying the drug-loaded nanocarrier-based gel to skin. The in vivo efficacies of the nanocarrier-based formulations were also tested in a scopolamine-induced amnesia model. A significant improvement in cognitive function was observed in mice treated with the nanocarrier-based formulations compared with the control group. A decrease in cognitive function was observed upon oral delivery of a drug suspension compared with the transdermally administered nanocarrier. These find- ings showed a reduced transfer latency over the period of 3 days, which indicated the sustained and controlled release of the drug from the developed nanocarriers when adminis- tered via the transdermal route.223 Studies have demonstrated that curcumin decreases the in vitro and in vivo Aβ formation from APP and also inhibits the aggregation of Aβ into pleated sheets.225–228 Curcumin has been incorporated into SLNs and NCLs for other therapeutic purposes.229–234 Kakkar et al evaluated curcumin-loaded SLNs for brain delivery in rats via the oral route.36 The results showed that drug-loaded SLNs increased the activity of AChE compared to the free drug, and the concentration of curcumin was increased by twofold in the brain compared to the free drug when both treatments were orally administered. Although a cerebral ischemic reperfusion injury animal model was used in the study, these SLNs can be used for drug release in the brain for the treatment of AD.36 SLNs and NCLs that are chosen as drug carriers and administered in vivo can be transported to the CNS34,165,194,235–238 and may be useful in the treatment of AD. Liposomes Liposomes are vesicles consisting of one or more phospholipid bilayers concentrically oriented around an aqueous compart- ment239 that serve as carriers of lipophilic or hydrophilic drugs.240,241 Various processes can be used to prepare lipo- somes, such as hydration of a thin lipid film242–244 followed by agitation,245–248 sonication,249–254 extrusion,251,255–258 high-pressure homogenization,259–262 or reverse-phase evaporation.263–266 Liposomes may contain a single lipid bilayer or multiple bilayers around the inner aqueous compartment and are there- fore classified as unilamellar and multilamellar, respectively.267 Liposomes are classified by their lamellar size as small unilamellar vesicles with diameters of 20–100 nm, large unilamellar vesicles with diameters exceeding 100 nm, giant unilamellar vesicles with diameters up to 1 µm, oligolamel- lar vesicles with diameters of 0.1–1 µm, and multilamellar vesicles with diameters up to 500 nm (Figure 4).268 In the literature, liposomes are classified as niosomes, transfersomes, ethosomes, and phytosomes. Niosomes are formed by self-assembly of nonionic surfactants in an aque- ous dispersion and they are flexible and more stable than liposomes, which reduces the flux of drugs in comparison to conventional liposomes.269 Transfersomes are deform- able vesicles composed of phospholipids270 that are usually administered via the transdermal route.271 Ethosomes are either conventional liposomes or are transfersomes con- taining up to 10% ethanol, which can promote the solubi- lization of hydrophilic drugs.272 Phytosomes are produced by binding individual components of herbal extracts to phosphatidylcholine.273 Yang et al formulated rivastigmine liposomes and cell- penetrating peptide (CPP)-modified liposomes to improve the distribution of rivastigmine in the brain, enhance the pharmacodynamics via intranasal administration, and mini- mize side effects.37 The results showed that the concentra- tions of rivastigmine across the BBB were significantly www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4991 Nanotechnology-based drug delivery for Alzheimer’s different after 8 hours, reaching higher concentration values when CPP liposomes and liposomes were used compared to the free drug. The biodistribution of rivastigmine in the cerebellum was not found when free drug was administered intranasally or intravenously. The average rivastigmine concentration in CNS cerebral tissues was higher following intranasal administration of modified liposomes compared with liposomes, and the average rivastigmine concentration was significantly higher for the modified liposomes in the hippocampus, cortex, and olfactory region at 15 minutes to 60 minutes. The authors suggest that rivastigmine-loaded liposomes, especially-modified liposomes, improve the brain delivery and enhance pharmacodynamics with respect to BBB penetration and the nasal olfactory pathway into the brain after intranasal administration.37 In a study designed by Kumaraswamy et al, liposomes were obtained using the thin-film hydration technique.39 Thermal studies showed that the beta-sheet blocker was located in the hydrophobic core, where it acted to lower the surface tension. This property made these liposomes a suitable therapeutic agent for the prevention of amyloid aggregation by binding with Aβ in the brain.39 Many techniques are used to target liposomes across the BBB. These strategic techniques include the conjugation of drugs and monoclonal antibodies against endogenous receptors in the BBB173,274,275 or liposomes or other nanodevices coated with polysorbate 80, cationic macromolecules, peptides, or antibodies against BBB receptors or Aβ peptides173,276–279 to cross the BBB and to be targeted to the brain. Liposomes functionalized with an anti-transferrin recep- tor antibody can cross the BBB. The functionalization of liposomes gave higher values of uptake and permeability across the barrier model in comparison to non-decorated liposomes.280 Liposomes were functionalized with a modified cell-penetrating TAT peptide, which increased the permeabil- ity of curcumin-loaded liposomes across a BBB model.40 Mono- and dual-decorated liposomes were prepared by immobilization of anti-transferrin monoclonal antibody (MAb) against transferrin receptor in BBB and a peptide ana- log of apolipoprotein (PAA) to target low-density lipoprotein receptor in BBB. The major results showed liposome uptake and transport across the human microvascular endothelial cells (hCMEC/D3) used as a model barrier was significantly affected by decoration with PAA or MAb, and that the double immobilization with ligands in the liposomes exerted an addi- tive effect in the BBB targeting. The mechanism of targeting was confirmed to be vesicle transcytosis. In vivo study was carried out in mice, and the results showed that MAb and dual ligands (MAb and PAA) increased brain targeting compared to nontargeted liposomes. The authors appointed a contradic- tion between in vitro and in vivo results. PAA was found to target BBB and increase the in vitro targeting potential of MAb-decorated liposomes, but not in vivo, because in vitro studies were carried out in the presence of serum proteins in the middle of cell culture, revealing their important role in targeted-nanoformulation performance.41 Another published study explored the use of MAb in lipo- somes loaded with curcumin analog. This study compared Figure 4 Main pathways for nanosystems to cross the blood–brain barrier to target to brain. Abbreviations: CNS, central nervous system; NCLs, nanostructured lipid carriers; NPs, nanoparticles. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4992 Fonseca-Santos et al the ability of both curcumin analog- and curcumin-loaded liposomes and showed a high affinity for senile plaques on postmortem brain tissue of AD patients. The ability of both liposomes to delay Aβ 1-42 peptide aggregation was confirmed. However, the decoration of the curcumin-derivative lipo- somes with the MAb improved significantly the intake by the BBB cellular model. These results prove the potential of such multifunctional liposomes for application in AD treatment and diagnosis.42 Curcumin-conjugated liposomes were developed and the results showed significant amounts of labeled Aβ deposits in postmortem brain tissue of AD patients. In vivo injection in the hippocampus and in the neocortex of mice showed that curcumin-conjugated nanoliposomes were able to specifically stain the Aβ deposits.43 Thus, these liposome formulations can be applied in diagnosis and targeted drug delivery in AD. Curcumin derivative maintaining the planarity was developed to obtain conjugated liposomes. Surface plasmon resonance experiments indicated that the liposomes expos- ing the curcumin derivative had extremely high affinity for Aβ 1-42 fibrils, likely because of the occurrence of multivalent interactions, whereas those exposing non-planar curcumin did not bind to Aβ 1-42 .44 Ligand-functionalized nanoliposomes for targeted delivery of galantamine have also been designed. The major result revealed by confocal microscopy was that the ligand-function- alized nanoliposomes facilitated galantamine uptake into PC12 neuronal cells.45 Nevertheless, in vivo uptake studies should be should be performed as well as testing in animal models of AD to demonstrate the effectiveness of the nanosystem. Liposomes were prepared by the lipid hydration method to sustain the effect of rivastigmine in the brain. Rivastigmine-loaded liposomes and rivastigmine solution were administered via the subcutaneous route in an aluminum chloride-induced Alzheimer’s model. Both formulations improved the deterioration of spatial memory induced by aluminum chloride, with liposomes having a superior effect. Though the rivastigmine solution significantly attenuated AChE activity, rivastigmine-loaded liposomes succeeded in normalizing AChE.38 The delivery of liposomes to the brain can be attained via the intranasal route to overcome the BBB,169,281,282 and liposomes can cross the BBB by transport lipid-mediated free diffusion or lipid-mediated endocytosis.283 Rivastigmine- loaded liposomes were prepared using the lipid hydration method for delivery into the brain via the intranasal route. Intranasally delivered liposomes were compared to the orally delivered free drug group. The results showed that maximum concentration was tenfold higher in plasma and the half-time was significantly different for the intranasally delivered liposome group compared to the intranasally delivered free drug group or the orally delivered free drug group.46 Rivastigmine-loaded liposomes were administered orally and intraperitoneally in an AD animal model, and the results showed the highest AChE inhibition with the use of rivastigmine–sodium taurocholate liposomes.47 The transport of rivastigmine-containing liposomes across Caco-2 cells has also been studied. The highest cumu- lative amount of rivastigmine to pass through the Caco-2 cell cultures was found for the rivastigmine–sodium taurocholate solution compared to the rivastigmine–sodium taurocholate liposome. Rivastigmine liposomes and molecular solutions were also administered to animals and the AChE activity cal- culated using blood and brain tissue samples, and the highest value of AChE inhibition was observed for the rivastigmine and sodium taurocholate liposomes.48 Folic acid niosomes were prepared using different non- ionic surfactants and cholesterol via the lipid hydration tech- nique, and ex vivo perfusion studies were performed using a rat model. The drug was found to be absorbed through the nasal cavity at the end of 6 hours.49 Folic acid has been associ- ated with an improvement in the response of cholinesterase inhibitors in people with AD.284 Freeze-dried niosomes loaded with G. biloba extract were developed with improved oral bioavailability. The in vivo distribution of GbE niosomes in the rat showed that the flavonoid glycoside biomarker content in the brain was significantly higher for the niosome group than for the G. biloba extract tablet group.51 Change in pharmacokinetic behavior, in vivo distribution, and higher accumulation in the brain with the use of the plant drug extract or AChE inhibitor drugs indicate the pharmacotherapeutic uses of niosomes in diseases affecting the brain. Phytosomes containing G. biloba were administered to rats via the oral route. Compared to a sodium nitrite treatment, these phytosomes were able to increase the activities of antioxidant enzymes in all the brain regions.50 However, many of the early trials used unsatisfac- tory methods, were small, and publication bias cannot be excluded. The evidence that G. biloba has predictable and clinically significant benefit for people with dementia or cognitive impairment is inconsistent and unreliable.285 Surfactant-based systems Surfactant-based drug delivery systems are different drug delivery systems in which surfactant molecules are www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4993 Nanotechnology-based drug delivery for Alzheimer’s self-aggregated, usually in the presence of water, to form structures with variable parameters depending on the con- centration of the surfactant, the presence of salts, or the temperature. These aggregates become more organized even when oils or other components such as other surfactants are added to the surfactant–water system.286 Thus, MEs, nanoemulsions (NEs), and lyotropic LC mesophases with different geometries can be generated.286,287 MEs are usually thermodynamically stable isotropic liq- uids formed by mixing oil, water, and surfactants together. NEs, by contrast, are conventional emulsions that contain very small particles. The droplet sizes of MEs are between 10 and 140 nm,288 which results in optically transparent and thermodynamically stable systems.289,290 NEs are up to 140 nm in diameter and are not transparent and less thermodynami- cally stable than MEs (Figure 5).290 The two systems are very different because NEs are formed by mechanical shearing and ME phases are formed by self-assembly.291 Other parameters can distinguish MEs from NEs: MEs are more stable in long-term storage than NEs; MEs can be agitated, cooled, or heated and then returned to their original conditions, whereas NEs cannot return to their original condi- tions; MEs have a homogeneous droplet size while NEs have a range of heterogeneously sized droplets; and MEs may or may not contain spherical droplets due to the lower interfacial tension while NEs consist of spherical droplets due to the large Laplace pressure acting upon them.290 MEs are formed from spontaneous mixtures of oils, water, and surfactants,292,293 though it is often necessary to apply stirring or heating292,294 to facilitate the formation of MEs due to kinetic energy barriers that must be overcome or mass transport limitations that inhibit their spontaneous formation.290 NEs are formed using the input of some external energy provided by high-pressure homogenizers,295–297 microfluidizers,298 and sonication methods299 to convert the mixture into a colloidal dispersion or phase inversion. Spontaneous emulsification methods296 can then be used to form NEs. NEs containing curcumin were developed for intranasal delivery, and the results from behavioral experiments showed improved memory and learning in the group treated with curcumin-loaded NEs compared with the group treated with the pure drug.300 MEs were developed for transdermal deliv- ery in order to manage AD, and mice given MEs containing huperzine A showed improved cognitive functions compared to mice given the drug in suspension via the oral route.35 An ME-based patch for the transdermal delivery of huperzine A and ligustrazine phosphate was developed, and the results showed that, unlike the monotherapy, the combined therapy had a synergistic effect against amnesia induced in mice by 9 days after administration.301 The intranasal administration of β-asarone-loaded MEs resulted in a ratio of AUC brain /AUC plasma that was significantly higher compared to intravenous administration.52 Another study was developed, in which an anticholinesterase alka- loidal extract from Tabernaemontana divaricata was loaded into MEs. The results showed a good stability of the MEs and an AChE activity of more than 80% by 180 days. More- over, the skin permeation and retention of the formulation increased within 24 hours after transdermal delivery of the extract.53 Tacrine-loaded MEs showed a rapid absorption and nose-to-brain transmission that was twofold higher than that of an intranasally administered drug solution. A larger amount of tacrine was transported into the brains of scopolamine-induced amnesic mice after the intranasal Figure 5 Photograph of microemulsion and nanoemulsion. Note: enlarged areas show schematics of the size of droplets formed. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4994 Fonseca-Santos et al administration of tacrine-loaded MEs. These mice also showed the fastest recovery of memory loss.54 LCs consist of matter in a state with properties between those of conventional liquids and those of solid crystals.302 In other words, LCs have the structural behavior and rigidity of a solid combined with the mobility, disorder, and fluidity of an isotropic liquid.303 Lyotropic mesophases can be con- sidered to be micelles with ordered molecular arrangements characterized by alternating hydrophobic and hydrophilic regions.304 By increasing the concentration of surfactants, lamellar, hexagonal, and cubic liquid-crystalline forms can be generated (Figure 6).305 The lamellar phase is formed from bilayers separated by layers of surfactants and solvents, which forms a one- or two-dimensional network.306 In the hexagonal phase, the aggregates are formed by the arrangement of long cylinders that form two- or three-dimensional structures.307 Lyotropic cubic phases have more complicated structures consisting of a curved, bicontinuous lipid bilayer that extends in three dimensions to generate two interpene trating, but non- contacting, aqueous nanochannels.308,309 Self-assembly systems display phase transformations and notable in situ thickening after administration. These systems are also of interest in relation to drug delivery to the body cavities.305 The intranasal administration of LCs can be interesting due to the dilution of LCs in nasal fluid, which promotes the phase transition to a hexagonal or cubic LC that can prolong the residence time of the formulation in contact with the mucosa.310 In the case of LC phases, the mechanism of mucoadhesion most likely involves the rheological proper- ties of the system, which are similar to those of in situ gelling vehicles.311 Due to their high viscosity, hexagonal and cubic phases have been suggested as mucoadhesives. However, the viscosity of cubic phases can hinder their nasal admin- istration. To circumvent this handling problem, precursor formulations of liquid-crystalline mesophases have been proposed.312 Numerous studies have shown that MEs and lamellar phase can be used as a precursor of the hexagonal or cubic phases310,311,313–317 after the stimuli in situ. LC systems significantly increased the transdermal delivery of the T. divaricata extract at 24 hours. When loaded into an LC system, an alkaloidal extract from the T. divaricata stem may act as an alternative percutaneous formulation for enhancing the acetylcholine level in patients with AD.53 The nasal administration of LCs in the treatment and management of AD is a tool that has been unexplored by researchers. LCs have been shown to be an optimal system for intranasal administration; in situ gelation occurs by dilution by nasal fluid and results in increased residence time in the nasal cavity and targeting of drugs to the brain. Remarks and challenges Approximately 15 million people worldwide are currently afflicted by AD.3 This number is expected to increase fourfold by 2050.3 Nanotechnology offers the potential for designing drug delivery systems with many properties. In the context of treating AD, these types of nanosystems could efficiently carry and deliver drugs and other neuroprotective molecules to the brain.4,318,319 The intranasal route plays a role in overcoming the BBB and targeting the drugs directly to the brain.282,319–325 However, the oral, dermal, and intra- venous routes can be used to administration of nanodevices Figure 6 Schematic representation of lamellar, hexagonal, and cubic liquid crystal mesophases formed by surfactant molecules’ self-assembly. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4995 Nanotechnology-based drug delivery for Alzheimer’s to target to the brain passing by BBB276,326–329 to enhanced bioavailability, pharmacodynamic properties, and decreased adverse effects of these drugs to maximize pharmacotherapy in patients with AD. Though the registry of patents for nanotechnology- based products is currently increasing,323,330,331 clinical trials are needed to evaluate their clinical efficacy and potential toxicological effects to human health.332 In the near future, neurologists and patients will benefit from suitable nano- technology-based drug delivery systems that could lead to improved therapeutic outcomes with reduced costs. Although there are no clinical studies on the use of nanotechnology to treat AD, nanotechnology is also predicted to alter health care in neurology, providing novel methods for identifying AD19 and customizing a patient’s therapeutic profile. Acknowledgments The authors are grateful to the São Paulo Research Founda- tion (FAPESP) (São Paulo, Brazil, Coordination for the Improvement of Higher Education Personnel (CAPES) (Brasília, Brazil) for research fellowships and Programa de Apoio ao Desenvolvimento Científico (PADC-FCF-UNESP) for financial support. Author contributions BFS made substantial contributions in conceiving this review, searching the bibliographical data, conducting the analysis, and critically revising it for important intellectual content. MPDG and MC conducted the analysis and revised it critically for important intellectual content. All authors gave final approval of the version to be published. Disclosure The authors report no conflicts of interest in this work. References 1. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118–1127. 2. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010; 362(4):329–344. 3. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–245. 4. Sood S, Jain K, Gowthamarajan K. Intranasal therapeutic strate- gies for management of Alzheimer’s disease. J Drug Target. 2014; 22(4):279–294. 5. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis. 2012;2012:728983. 6. Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315–335. 7. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719–739. 8. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepa- totoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992–998. 9. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholin- esterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5): 379–397. 10. Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79(1):134–143. 11. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharma- cotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 2007;46(7):599–612. 12. Arias JL, editor. Key aspects in nanotechnology and drug delivery. In: Nanotechnology and Drug Delivery. Volume 1: Nanoplatforms in Drug Delivery. Boca Raton: CRC Press; 2015:1–27. 13. Sharma S, Singh A. Nanotechnology based targeted drug delivery: current status and future prospects for drug development, drug dis- covery and development. In: Kapetanović IM, editor. Drug Discov- ery and Development: Present and Future. Croatia: InTech; 2011: 427–462. 14. Suri K, Wolfram J, Shen H, Ferrari M. Advances in nanotechnology- based drug delivery platforms and novel drug delivery systems. In: Singh M, Salnikova M, editors. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. San Diego: Academic Press; 2015:41–58. 15. Parveen S, Sahoo S. Nanomedicine: clinical applications of poly- ethylene glycol conjugated proteins and drugs. Clin Pharmacokinet. 2006;45(10):965–988. 16. Orive G, Hernández RM, Rodríguez Gascón A, Domı́nguez-Gil A, Pedraz JL. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol. 2003;14(6):659–664. 17. Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design A review. Journal of Saudi Chemical Society. 2014; 18(2):85–99. 18. Betancourt T, Doiron A, Homan KA, Brannon-Peppas L. Controlled release and nanotechnology. In: de Villiers MM, Aramwit P, Kwon GS, editors. Nanotechnology in Drug Delivery. New York: Springer; 2009:283–312. 19. Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedi- cine. 2011;7(5):521–540. 20. Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis. 2008;13(2):199–223. 21. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2008;70(1):75–84. 22. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008;1200:159–168. 23. Zhang C, Wan X, Zheng X, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice. Biomateri- als. 2014;35(1):456–465. 24. Zhang C, Chen J, Feng C, et al. Intranasal nanoparticles of basic fibro- blast growth factor for brain delivery to treat Alzheimer’s disease. Int J Pharm. 2014;461(1–2):192–202. 25. Brambilla D, Verpillot R, De Kimpe L, Taverna M, Le Droumaguet B, Andrieux K. Nanoparticles against Alzheimer’s disease: PEG-PACA nanoparticles are able to link the Aβ-peptide and influence its aggrega- tion kinetic. J Biotechnol. 2010;150 Suppl:27. 26. Brambilla D, Verpillot R, Taverna M, et al. New method based on capil- lary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide. Anal Chem. 2010;82(24):10083–10089. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4996 Fonseca-Santos et al 27. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characteriza- tion, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76(2):189–199. 28. Fazil M, Md S, Haque S, et al. Development and evaluation of rivastig- mine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci. 2012;47(1):6–15. 29. Amorim Cde M, Couto AG, Netz DJ, de Freitas RA, Bresolin TM. Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan. Nanomedicine. 2010;6(6):745–752. 30. Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target. 2013;21(3):300–311. 31. Sood S, Jain K, Gowthamarajan K. Curcumin-donepezil–loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer’s disease model. Alzheimers Dement. 2013;9(4):P299. 32. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1–2):179–185. 33. Frozza RL, Salbego C, Bernardi A, et al. Incorporation of resveratrol into lipid-core nanocapsules improves its cerebral bioavailability and reduces the Aβ-induced toxicity. Alzheimers Dement. 2011;7(4):S114. 34. Bondì ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (Lond). 2009;5(1):25–32. 35. Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB. Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm. 2013;446(1–2):16–23. 36. Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 2013;85 (3 Pt A):339–345. 37. Yang ZZ, Zhang YQ, Wang ZZ, Wu K, Lou JN, Qi XR. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm. 2013;452(1–2): 344–354. 38. Ismail MF, Elmeshad AN, Salem NA. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease. Int J Nanomedicine. 2013;8:393–406. 39. Kumaraswamy P, Sethuraman S, Krishnan UM. Liposomal delivery of a beta sheet blocker peptide for the treatment of Alzheimer’s disease. Alzheimers Dement. 2012;8(4 Suppl):P705. 40. Sancini G, Gregori M, Salvati E, et al. Functionalization with TAT- peptide enhances blood–brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide. J Nanomed Nanotechnol. 2013;4(3). 41. Markoutsa E, Papadia K, Giannou AD, et al. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm Res. 2014;31(5):1275–1289. 42. Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem. 2014;80:175–183. 43. Lazar AN, Mourtas S, Youssef I, et al. Curcumin-conjugated nanoli- posomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine. 2013;9(5):712–721. 44. Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanolipo- somes with very high affinity for amyloid-β1-42 peptide. Biomaterials. 2011;32(6):1635–1645. 45. Mufamadi MS, Choonara YE, Kumar P, et al. Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm. 2013;448(1):267–281. 46. Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for deliv- ery into the brain through intranasal route. Acta Pharm. 2008; 8(3):287–297. 47. Mutlu NB, Değim Z, Yılmaz Ş, Eşsiz D, Nacar A. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formula- tions. Drug Dev Ind Pharm. 2011;37(7):775–789. 48. Degim Z, Mutlu NB, Yilmaz S, Eşsiz D, Nacar A. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie. 2010;65(1):32–40. 49. Ravouru N, Kondreddy P, Korakanchi D, Haritha M. Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discov Technol. 2013;10(4):270–282. 50. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activ- ity of Ginkgo biloba phytosomes in rat brain. Phytother Res. 2006; 20(11):1013–1016. 51. Jin Y, Wen J, Garg S, et al. Development of a novel niosomal sys- tem for oral delivery of Ginkgo biloba extract. Int J Nanomedicine. 2013;8:421–430. 52. Zhang LK, Xu RX, Jiang M, et al. Evaluation of brain-targeting of β-asarone microemulsion by intranasal administration. Chinese Tra- ditional and Herbal Drugs. 2014;45(1):86–89. 53. Chaiyana W, Rades T, Okonogi S. Characterization and in vitro perme- ation study of microemulsions and liquid crystalline systems contain- ing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. Int J Pharm. 2013;452(1–2):201–210. 54. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008;22(2):116–124. 55. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–766. 56. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353–356. 57. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007;4(1):13–27. 58. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631–639. 59. Bush AI. The metal theory of Alzheimer’s disease. J Alzheimers Dis. 2013;33 Suppl 1:S277–S281. 60. Gouras GK, Beal MF. Metal chelator decreases Alzheimer β-amyloid plaques. Neuron. 2001;30(3):641–642. 61. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydro- gen peroxide production and metal reduction. J Biol Chem. 1999; 274(52):37111–37116. 62. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci. 1998;158(1):47–52. 63. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer’s disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 1999;274(33):23223–23228. 64. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001;30(3):665–676. 65. Bartus RT, Emerich DF. Cholinergic markers in Alzheimer disease. JAMA. 1999;282(23):2208–2209. 66. Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett. 1980;20(3):373–377. 67. Henke H, Lang W. Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer- type patients. Brain Res. 1983;267(2):281–291. 68. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients car- rying apolipoprotein epsilon 4 allele. Neurosci Lett. 1995;187(2): 79–82. 69. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CMC. Platelet phospholipase A2 activity in Alzheimer’s disease and mild cognitive impairment. J Neural Transm. 2004;111(5):591–601. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4997 Nanotechnology-based drug delivery for Alzheimer’s 70. Gattaz WF, Talib LL, Schaeffer EL, Diniz BS, Forlenza OV. Low plate- let iPLA 2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study. J Neural Transm. 2014;121(2):193–200. 71. Gattaz WF, Cairns NJ, Levy R, Förstl H, Braus DF, Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer’s disease. Eur Arch Psychiatry Clin Nuerosci. 1996;246(3):129–131. 72. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72(5):1858–1862. 73. Gong CX, Grundke-Iqbal I, Iqbal K. Targeting tau protein in Alzheimer’s disease. Drugs Aging. 2010;27(5):351–365. 74. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegenera- tion in Alzheimer’s disease and related disorders. Nat Rev Neurosci. 2007;8(9):663–672. 75. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21(2):195–218. 76. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3(4):169–176. 77. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging. 2001;22(6):903–908. 78. Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytok- ines and reactive oxygen species are produced. J Neuroimmunol. 1999;93(1–2):182–193. 79. Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol. 2005;37(2):289–305. 80. Li C, Zhao R, Gao K, et al. Astrocytes: implications for neuroinflam- matory pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2011;8(1):67–80. 81. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003; 27(3):325–355. 82. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer’s disease. Neurochem Int. 2001;39(5–6):333–340. 83. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the pre- clinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292. 84. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. 85. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cog- nitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279. 86. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recom- mendations from the National Institute on Aging-Alzheimer’s Asso- ciation workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–262. 87. Teng E, Ringman JM, Ross LK, et al; Alzheimer’s Disease Research Centers of California-Depression in Alzheimer’s Disease Investiga- tors. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008;16(6):469–477. 88. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002; 10(2):125–128. 89. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Qual- ity Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143–1153. 90. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol. 1987; 44(3):258–262. 91. Bird JM, Levy R, Jacoby RJ. Computed tomography in the elderly: changes over time in a normal population. Br J Psychiatry. 1986; 148:80–85. 92. Luxenberg JS, Haxby JV, Creasey H, Sundaram M, Rapoport SI. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration. Neurology. 1987;37(7):1135–1140. 93. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol. 2000;47(4):430–439. 94. Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58(8):1188–1196. 95. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64(7):1015–1020. 96. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3): 843–854. 97. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diag- nostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238–1248. 98. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501–508. 99. Dukart J, Kherif F, Mueller K, et al; Alzheimer’s Disease Neuroim- aging Initiative. Generative FDG-PET and MRI model of aging and disease progression in Alzheimer’s disease. PLoS Comput Biol. 2013;9(4):e1002987. 100. Choi SR, Schneider JA, Bennett DA, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26(1):8–16. 101. Clark CM, Schneider JA, Bedell BJ, et al; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–283. 102. Lister-James J, Pontecorvo MJ, Clark C, et al. Florbetapir f-18: a his- topathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med. 2011;41(4):300–304. 103. Johnson KA, Sperling RA, Gidicsin CM, et al; AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5 Suppl):S72–S83. 104. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–329. 105. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74(9):1206–1209. 106. Osimani A, Berger A, Friedman J, Porat-Katz BS, Abarbanel JM. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects. J Geriatr Psychiatry Neurol. 2005; 18(1):33–38. 107. Vargas AP, Carod-Artal FJ, Del Negro MC, Rodrigues MP. [Dementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patient]. Arq Neuropsiquiatr. 2000;58(2B):578–582. Portuguese. 108. Fleming KC, Adams AC, Petersen RC. Dementia: diagnosis and evaluation. Mayo Clin Proc. 1995;70(11):1093–1107. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 4998 Fonseca-Santos et al 109. Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Apolipoprotein E plasma level and genotype – /INS; risk of demen- tia in 76,000 individuals from the general population. J Neurol Sci. 2013;333:e342. 110. Goldman JS, Hahn SE, Catania JW, et al; American College of Medi- cal Genetics and the National Society of Genetic Counselors. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6):597–605. 111. Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain target- ing for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(1):35–47. 112. Härtig W, Paulke BR, Varga C, Seeger J, Harkany T, Kacza J. Electron microscopic analysis of nanoparticles delivering thio- flavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer’s disease. Neurosci Lett. 2003;338(2):174–176. 113. Massoud F, Léger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–588. 114. Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011;83(12):1403–1412. 115. Bentley P, Driver J, Dolan RJ. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. Brain. 2009;132(Pt 9):2356–2371. 116. Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf. 2009;8(1):89–109. 117. Lipton SA. The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2(2):155–165. 118. Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. AJNR Am J Neuroradiol. 2001;22(10):1813–1824. 119. Molinuevo JL, Lladó A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias. Am J Alzheimers Dis Other Demen. 2005;20(2):77–85. 120. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry. 1999;14(1):3–47. 121. Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30(33):11246–11250. 122. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of meman- tine: an update. Curr Neuropharmacol. 2008;6(1):55–78. 123. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699–723. 124. Srinivasan M, Lahiri DK. Significance of NF-κB as a pivotal thera- peutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis. Expert Opin Ther Targets. 2015;19(4): 471–487. 125. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. Scientific World Journal. 2012;2012:756357. 126. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346. 127. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood–brain barrier. Int J Nanomedicine. 2014;9:795–811. 128. Haque S, Md S, Alam MI, Sahni JK, Ali J, Baboota S. Nanostructure- based drug delivery systems for brain targeting. Drug Dev Ind Pharm. 2012;38(4):387–411. 129. Paolino D, Cosco D, Molinaro R, Celia C, Fresta M. Supramolecular devices to improve the treatment of brain diseases. Drug Discov Today. 2011;16(7–8):311–324. 130. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420. 131. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007;31(5):249–261. 132. Oesterling BM, Gulati A, Joshi MD. Nanocarrier-based approaches for treatment and detection of Alzheimer’s disease. J Nanosci Nano- technol. 2014;14(1):137–156. 133. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35–58. 134. Sainsbury F, Zeng B, Middelberg APJ. Towards designer nanoemul- sions for precision delivery of therapeutics. Curr Opin Chem Eng. 2014;4:11–17. 135. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damge C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell. 1987;61(1–2): 69–76. 136. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94(6): 1187–1195. 137. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998;5(6):415–441. 138. Kreuter J. Nanoparticles and nanocapsules – new dosage forms in the nanometer size range. Pharm Acta Helv. 1978;53(2):33–39. 139. Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights. 2007;2:147–157. 140. Couvreur P, Barratt G, Fattal E, Vauthier C. Nanocapsule technology: a review. 2002;19(2):36. 141. Boudad H, Legrand P, Lebas G, Cheron M, Duchêne D, Ponchel G. Com- bined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm. 2001;218(1–2):113–124. 142. Souto EB, Severino P, Santana MHA. Preparação de nanopartículas poliméricas a partir da polimerização de monômeros: parte I [Prepara- tion of polymeric nanoparticles by polymerization of monomers: part I]. Polímeros. 2012;22:96–100. Portuguese. 143. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Carbohydr Polym. 2013;94(2):940–945. 144. Arora S, Gupta S, Narang RK, Budhiraja RD. Amoxicillin loaded chito- san-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori. Sci Pharm. 2011;79(3):673–694. 145. Mainardes RM, Evangelista RC. Praziquantel-loaded PLGA nano- particles: preparation and characterization. J Microencapsul. 2005; 22(1):13–24. 146. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1–2):137–144. 147. Alshamsan A. Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles. Saudi Pharm J. 2014;22(3):219–222. 148. Mainardes RM, Gremião MPD. Nanoencapsulation and charac- terization of zidovudine on poly(L-lactide) and poly(L-lactide)- poly(ethylene glycol)-blend nanoparticles. J Nanosci Nanotechnol. 2012;12(11):8513–8521. 149. Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Novel hydro- philic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63(1):125–132. 150. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Prepara- tion of poly(dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187(2):143–152. www.dovepress.com www.dovepress.com www.dovepress.com International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 4999 Nanotechnology-based drug delivery for Alzheimer’s 151. Mazzarino L, Coche-Guérente L, Labbé P, Lemos-Senna E, Borsali R. On the mucoadhesive properties of chitosan-coated polycapro- lactone nanoparticles loaded with curcumin using quartz crystal microbalance with dissipation monitoring. J Biomed Nanotechnol. 2014;10(5):787–794. 152. Bilati U, Allémann E, Doelker E. Development of a nanoprecipita- tion method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67–75. 153. Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm. 2014;87(3):510–517. 154. Hu X, Guo Y, Wang L, Hua D, Hong Y, Li J. Coenzyme Q 10 nano- particles prepared by a supercritical fluid-based method. J Supercrit Fluids. 2011;57(1):66–72. 155. Chu KS, Hasan W, Rawal S, et al. Plasma, tumor and tissue phar- macokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine. 2013;9(5):686–693. 156. Galloway AL, Murphy A, DeSimone JM, et al. Development of a nanoparticle-based influenza vaccine using the PRINT technology. Nanomedicine. 2013;9(4):523–531. 157. Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM. Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J Control Release. 2007;121(1–2):10–18. 158. Jain KK. Nanobiotechnology-based drug delivery to the central ner- vous system. Neurodegener Dis. 2007;4(4):287–291. 159. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. J Control Release. 2012;161(2): 264–273. 160. Barbu E, Molnàr E, Tsibouklis J, Górecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood– brain barrier. Expert Opin Drug Deliv. 2009;6(6):553–565. 161. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood–brain barrier by polysorbate 80-coated polybutylcyano- acrylate nanoparticles. Int J Pharm. 2006;310(1–2):213–219. 162. Soni S, Babbar AK, Sharma RK, Banerjee T, Maitra A. Pharmaco- scintigraphic evaluation of polysorbate 80-coated chitosan nano- particles for brain targeting. American Journal of Drug Delivery. 2005;3(3):205–212. 163. Jain KK. Nanoneurology. In: Applications of Biotechnology in Neurol- ogy. New York: Humana Press; 2013:283–294. 164. Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171–9182. 165. Kuo YC, Hong TY. Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline. Int J Pharm. 2014;465(1–2):132–142. 166. Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neu- rones. J Control Release. 2009;137(1):78–86. 167. Xin H, Sha X, Jiang X, et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. Biomaterials. 2012;33(5):1673–1681. 168. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little tox- icity against blood–brain barrier. Int J Pharm. 2005;295(1–2): 247–260. 169. Mainardes RM, Urban MC, Cinto PO, Chaud MV, Evangelista RC, Gremião MP. Liposomes and micro/nanoparticles as colloida